Literature DB >> 10329555

Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus.

J L Martínez-Torrecuadrada1, J P Langeveld, A Venteo, A Sanz, K Dalsgaard, W D Hamilton, R H Meloen, J I Casal.   

Abstract

African horse sickness virus (AHSV) causes a fatal disease in horses. The virus capsid is composed of a double protein layer, the outermost of which is formed by two proteins: VP2 and VP5. VP2 is known to determine the serotype of the virus and to contain the neutralizing epitopes. The biological function of VP5, the other component of the capsid, is unknown. In this report, AHSV VP5, expressed in insect cells alone or together with VP2, was able to induce AHSV-specific neutralizing antibodies. Moreover, two VP5-specific monoclonal antibodies (MAbs) that were able to neutralize the virus in a plaque reduction assay were generated. To dissect the antigenic structure of AHSV VP5, the protein was cloned in Escherichia coli using the pET3 system. The immunoreactivity of both MAbs, and horse and rabbit polyclonal antisera, with 17 overlapping fragments from VP5 was analyzed. The most immunodominant region was found in the N-terminal 330 residues of VP5, defining two antigenic regions, I (residues 151-200) and II (residues 83-120). The epitopes were further defined by PEPSCAN analysis with 12mer peptides, which determined eight antigenic sites in the N-terminal half of the molecule. Neutralizing epitopes were defined at positions 85-92 (PDPLSPGE) for MAb 10AE12 and at 179-185 (EEDLRTR) for MAb 10AC6. Epitope 10AE12 is highly conserved between the different orbiviruses. MAb 10AE12 was able to recognize bluetongue virus VP5 and epizootic hemorrhagic disease virus VP5 by several techniques. These data will be especially useful for vaccine development and diagnostic purposes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329555     DOI: 10.1006/viro.1999.9680

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  A correlation between capsid protein VP2 and the plaque morphology of African horse sickness virus in cell culture.

Authors:  Mathilde L Schade-Weskott; Antoinette van Schalkwyk; J J O Koekemoer
Journal:  Virus Genes       Date:  2018-05-05       Impact factor: 2.332

2.  Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilization.

Authors:  S H Hassan; C Wirblich; M Forzan; P Roy
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Authors:  Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; Jose Maria Nieto; Javier Ortego; Peter Paul Clement Mertens
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

4.  A review of African horse sickness and its implications for Ireland.

Authors:  Geoffrey M Thompson; Stephen Jess; Archie K Murchie
Journal:  Ir Vet J       Date:  2012-07-05       Impact factor: 2.146

5.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

6.  B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Authors:  Evans M Mathebula; Frederika E Faber; Wouter Van Wyngaardt; Antoinette Van Schalkwyk; Alri Pretorius; Jeanni Fehrsen
Journal:  Onderstepoort J Vet Res       Date:  2017-02-24       Impact factor: 1.792

Review 7.  Adaptive strategies of African horse sickness virus to facilitate vector transmission.

Authors:  Anthony Wilson; Philip Scott Mellor; Camille Szmaragd; Peter Paul Clement Mertens
Journal:  Vet Res       Date:  2008-12-19       Impact factor: 3.683

8.  A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.

Authors:  Mine Aksular; Eva Calvo-Pinilla; Alejandro Marín-López; Javier Ortego; Adam C Chambers; Linda A King; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2018-10-08       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.